

Contents

Preface	xix
Acknowledgments	xx
CHAPTER 1 Pituitary Gland Therapies	1
1.1 Cushing's Disease	1
1.1.1 Pasireotide	1
1.1.1.1 Physiology	1
1.1.1.2 Mechanism of Action	2
1.1.1.3 Practice Guide	2
1.1.2 Retinoic Acid	3
1.1.2.1 Physiology	3
1.1.2.2 Mechanism of Action	3
1.1.2.3 Practice Guide	4
1.1.3 Dopaminergic Agonists	5
1.1.3.1 Physiology	5
1.1.3.2 Mechanism of Action	5
1.1.3.3 Practice Guide	5
1.1.4 Steroidogenesis Inhibitors	5
1.1.4.1 Physiology	5
1.1.4.2 Mechanism of Action	5
1.1.4.3 Practice Guide	6
1.1.5 Mifepristone	8
1.1.5.1 Physiology	8
1.1.5.2 Mechanism of Action	8
1.1.5.3 Practice Guide	8
1.2 Acromegaly	10
1.2.1 Somatostatin Analogs	10
1.2.1.1 Physiology	10
1.2.1.2 Mechanism of Action	11
1.2.1.3 Practice Guide	12
1.2.2 Growth Hormone Receptor Antagonists	12
1.2.2.1 Physiology	12
1.2.2.2 Mechanism of Action	12
1.2.2.3 Practice Guide	13
1.2.3 Dopaminergic Agonists	14
1.2.3.1 Physiology	14
1.2.3.2 Mechanism of Action	14
1.2.3.3 Practice Guide	14
1.3 Prolactinoma	15
1.3.1 Dopaminergic Agonists	15
1.3.1.1 Physiology	15
1.3.1.2 Mechanism of Action	16
1.3.1.3 Practice Guide	16
1.3.2 Temozolomide	17
1.3.2.1 Physiology	17

1.3.2.2	Mechanism of Action	17
1.3.2.3	Practice Guide	17
1.4	Adult Growth Hormone Insufficiency	19
1.4.1	Growth Hormone	19
1.4.1.1	Physiology	19
1.4.1.2	Mechanism of Action	21
1.4.1.3	Practice Guide	21
1.5	Central Diabetes Insipidus	22
1.5.1	Desmopressin	22
1.5.1.1	Physiology	22
1.5.1.2	Mechanism of Action	22
1.5.1.3	Practice Guide	22
1.5.2	Water	24
1.5.2.1	Physiology	24
1.5.2.2	Mechanism of Action	24
1.5.2.3	Practice Guide	24
1.5.3	Natriuretic Agents	24
1.5.3.1	Physiology	24
1.5.3.2	Mechanism of Action	25
1.5.3.3	Practice Guide	25
1.5.4	Clofibrate, Chlorpropamide, and Carbamazepine	26
1.5.4.1	Physiology	26
1.5.4.2	Mechanism of Action	26
1.5.4.3	Practice Guide	26
1.6	Syndrome of Inappropriate ADH Secretion	28
1.6.1	Vaptans	28
1.6.1.1	Physiology	28
1.6.1.2	Mechanism of Action	28
1.6.1.3	Practice Guide	28
1.6.2	Fluid Restriction	28
1.6.2.1	Physiology	28
1.6.2.2	Mechanism of Action	29
1.6.2.3	Practice Guide	29
	Practice-Based Questions	30
	References	33

CHAPTER 2	Thyroid Gland Therapies	43
2.1	Hashimoto's Thyroiditis	43
2.1.1	Levothyroxine	43
2.1.1.1	Physiology	43
2.1.1.2	Mechanism of Action	44
2.1.2	Liothyronine	47
2.1.2.1	Physiology	47
2.1.2.2	Mechanism of Action	48
2.1.3	Selenium	49
2.1.3.1	Physiology	49
2.1.3.2	Mechanism of Action	50
2.2	Graves' Disease and Thyroid Eye Disease	51
2.2.1	Thionamides	51
2.2.1.1	Physiology	51
2.2.1.2	Mechanism of Action	51
2.2.2	Lugol's Iodine	53
2.2.2.1	Physiology	53
2.2.2.2	Mechanism of Action	53

2.2.3	<i>Iodide Transport Inhibitors</i>	54
2.2.3.1	Physiology	54
2.2.3.2	Mechanism of Action	54
2.2.4	<i>Glucocorticoids</i>	54
2.2.4.1	Physiology	54
2.2.4.2	Mechanism of Action	55
2.2.5	<i>Selenium</i>	55
2.2.5.1	Physiology	55
2.2.5.2	Mechanism of Action	55
2.2.6	<i>Beta-Blockers</i>	56
2.2.6.1	Physiology	56
2.2.6.2	Mechanism of Action	56
2.2.7	<i>Cholestyramine</i>	58
2.2.7.1	Physiology	58
2.2.7.2	Mechanism of Action	58
2.2.8	<i>Lithium</i>	58
2.2.8.1	Physiology	58
2.2.8.2	Mechanism of Action	58
2.2.9	<i>Teprotumumab</i>	59
2.2.9.1	Physiology	59
2.2.9.2	Mechanism of Action	59
2.3	<i>Riedel's Thyroiditis</i>	60
2.3.1	<i>Glucocorticoids</i>	60
2.3.1.1	Physiology	60
2.3.1.2	Mechanism of Action	60
2.3.2	<i>Rituximab</i>	60
2.3.2.1	Physiology	60
2.3.2.2	Mechanism of Action	61
2.4	<i>Thyroid Hormone Resistance</i>	61
2.4.1	<i>Beta-Blockers</i>	61
2.4.1.1	Physiology	61
2.4.1.2	Mechanism of Action	62
2.4.2	<i>Thyroid Hormone Replacement Therapy</i>	62
2.4.2.1	Physiology	62
2.4.2.2	Mechanism of Action	63
2.5	<i>TSH-Secreting Tumors</i>	64
2.5.1	<i>Somatostatin Receptor Ligands</i>	64
2.5.1.1	Physiology	64
2.5.1.2	Mechanism of Action	64
2.5.2	<i>Dopaminergic Agonists</i>	65
2.5.2.1	Physiology	65
2.5.2.2	Mechanism of Action	65
2.6	<i>Thyroid Cancer</i>	65
2.6.1	<i>Tyrosine Kinase Inhibitors</i>	65
2.6.1.1	Physiology	65
2.6.1.2	Mechanism of Action	66
2.6.2	<i>Radioactive Iodine Ablation</i>	67
2.6.2.1	Physiology	67
2.6.2.2	Mechanism of Action	67
2.6.3	<i>mTOR Inhibitors</i>	68
2.6.3.1	Physiology	68
2.6.3.2	Mechanism of Action	68
	<i>Practice-Based Questions</i>	69
	<i>References</i>	73

CHAPTER 3	Adrenal Gland Therapies	83
3.1	Primary Adrenal Insufficiency	83
3.1.1	Glucocorticoids	83
3.1.1.1	Physiology	83
3.1.1.2	Mechanism of Action	83
3.1.2	Mineralocorticoids	85
3.1.2.1	Physiology	85
3.1.2.2	Mechanism of Action	88
3.1.3	Androgens	89
3.1.3.1	Physiology	89
3.1.3.2	Mechanism of Action	89
3.2	Primary Hyperaldosteronism	91
3.2.1	Mineralocorticoid Antagonists	91
3.2.1.1	Physiology	91
3.2.1.2	Mechanism of Action	91
3.2.2	Amiloride	92
3.2.2.1	Physiology	92
3.2.2.2	Mechanism of Action	92
3.3	Pheochromocytomas and other Paraganglioma Syndromes	96
3.3.1	Alpha-Blockers	96
3.3.1.1	Physiology	96
3.3.1.2	Mechanism of Action	97
3.3.2	Beta-Blockers	98
3.3.2.1	Physiology	98
3.3.2.2	Mechanism of Action	98
3.3.3	Chemotherapy	99
3.3.3.1	Physiology	99
3.3.3.2	Mechanism of Action	99
3.3.4	Methyltyrosine	100
3.3.4.1	Physiology	100
3.3.4.2	Mechanism of Action	101
3.3.5	MIBG	101
3.3.5.1	Physiology	101
3.3.5.2	Mechanism of Action	101
3.3.6	Calcium Channel Blockers	102
3.3.6.1	Physiology	102
3.3.6.2	Mechanism of Action	102
3.4	Classic Congenital Adrenal Hyperplasia	103
3.4.1	Glucocorticoids	103
3.4.1.1	Physiology	103
3.4.1.2	Mechanism of Action	104
3.4.2	Mineralocorticoids	105
3.4.2.1	Physiology	105
3.4.2.2	Mechanism of Action	105
3.5	Nonclassic Congenital Adrenal Hyperplasia	106
3.5.1	Insulin Sensitizers	106
3.5.1.1	Physiology	106
3.5.1.2	Mechanism of Action	106
3.5.2	Oral Contraceptive Pills and Antiandrogens	107
3.5.2.1	Physiology	107
3.5.2.2	Mechanism of Action	107
	Practice-Based Questions	108
	References	113

CHAPTER 4	Pancreatic Gland Therapies	122
4.1	Diabetes Mellitus	122
4.1.1	Insulin	122
4.1.1.1	Physiology	122
4.1.1.2	Mechanism of Action	123
4.1.2	Biguanides	127
4.1.2.1	Physiology	127
4.1.2.2	Mechanism of Action	130
4.1.3	Meglitinides	131
4.1.3.1	Physiology	131
4.1.3.2	Mechanism of Action	132
4.1.4	Sulfonylureas	134
4.1.4.1	Physiology	134
4.1.4.2	Mechanism of Action	134
4.1.5	Dopaminergic Agonists	136
4.1.5.1	Physiology	136
4.1.5.2	Mechanism of Action	136
4.1.6	PPAR-Gamma Agonists	137
4.1.6.1	Physiology	137
4.1.6.2	Mechanism of Action	138
4.1.7	GLP-1 Agonists	139
4.1.7.1	Physiology	139
4.1.7.2	Mechanism of Action	139
4.1.8	SGLT-2 Inhibitors	142
4.1.8.1	Physiology	142
4.1.8.2	Mechanism of Action	143
4.1.9	DPP-4 Inhibitors	144
4.1.9.1	Physiology	144
4.1.9.2	Mechanism of Action	144
4.1.10	Alpha-Glucosidase Inhibitors	145
4.1.10.1	Physiology	145
4.1.10.2	Mechanism of Action	145
4.1.11	Amylin Agonists	146
4.1.11.1	Physiology	146
4.1.11.2	Mechanism of Action	146
4.2	Neuroendocrine Tumors	148
4.2.1	Telotristat	148
4.2.1.1	Physiology	148
4.2.1.2	Mechanism of Action	149
4.2.2	Acid-Lowering Drugs	150
4.2.2.1	Physiology	150
4.2.2.2	Mechanism of Action	152
4.2.3	Somatostatin Analogs	152
4.2.3.1	Physiology	152
4.2.3.2	Mechanism of Action	153
4.3	Hypoglycemia Syndromes	154
4.3.1	Somatostatin Analogs	154
4.3.1.1	Physiology	154
4.3.1.2	Mechanism of Action	154
4.3.2	Diazoxide and Diuretics	155
4.3.2.1	Physiology	155
4.3.2.2	Mechanism of Action	155
4.3.3	Calcium Channel Blockers	155

4.3.3.1	Physiology	155
4.3.3.2	Mechanism of Action	155
4.3.4	<i>mTOR Inhibitors</i>	155
4.3.4.1	Physiology	155
4.3.4.2	Mechanism of Action	156
4.3.5	<i>Phenytoin</i>	156
4.3.5.1	Physiology	156
4.3.5.2	Mechanism of Action	156
	Practice-Based Questions	158
	References	161
 CHAPTER 5 Parathyroid Gland and Bone Therapies		171
5.1	Primary Hyperparathyroidism	171
5.1.1	<i>Calcimimetics</i>	171
5.1.1.1	Physiology	171
5.1.1.2	Mechanism of Action	172
5.1.2	<i>Bisphosphonates</i>	173
5.1.2.1	Physiology	173
5.1.2.2	Mechanism of Action	174
5.2	Hypoparathyroidism	176
5.2.1	<i>Thiazide Diuretics</i>	176
5.2.1.1	Physiology	176
5.2.1.2	Mechanism of Action	176
5.2.2	<i>Active Vitamin D</i>	179
5.2.2.1	Physiology	179
5.2.2.2	Mechanism of Action	180
5.2.3	<i>Calcium</i>	181
5.2.3.1	Physiology	181
5.2.3.2	Mechanism of Action	181
5.2.4	<i>Recombinant Human PTH</i>	182
5.2.4.1	Physiology	182
5.2.4.2	Mechanism of Action	183
5.3	Paget's Disease of Bone	184
5.3.1	<i>Bisphosphonates</i>	184
5.3.1.1	Physiology	184
5.3.1.2	Mechanism of Action	184
5.3.2	<i>Calcitonin</i>	185
5.3.2.1	Physiology	185
5.3.2.2	Mechanism of Action	185
5.4	X-Linked Hypophosphatemia	186
5.4.1	<i>Phosphorus</i>	186
5.4.1.1	Physiology	186
5.4.1.2	Mechanism of Action	187
5.4.2	<i>Burosumab (FGF-23 Monoclonal Antibody)</i>	187
5.4.2.1	Physiology	187
5.4.2.2	Mechanism of Action	188
5.4.3	<i>Calcitriol</i>	188
5.4.3.1	Physiology	188
5.4.3.2	Mechanism of Action	188
5.5	Osteoporosis	189
5.5.1	<i>Bisphosphonates</i>	189
5.5.1.1	Physiology	189
5.5.1.2	Mechanism of Action	191
5.5.2	<i>RANK-L Inhibitors</i>	192

5.5.2.1	Physiology	192
5.5.2.2	Mechanism of Action	192
5.5.3	PTH Analogs	192
5.5.3.1	Physiology	192
5.5.3.2	Mechanism of Action	193
5.5.4	PTHrp Analogs	194
5.5.4.1	Physiology	194
5.5.4.2	Mechanism of Action	194
5.5.5	Anti-Sclerostin Inhibitors	196
5.5.5.1	Physiology	196
5.5.5.2	Mechanism of Action	196
5.5.6	Selective Estrogen Receptor Modulators	197
5.5.6.1	Physiology	197
5.5.6.2	Mechanism of Action	197
5.5.7	Hormone Replacement Therapy (Estrogen)	198
5.5.7.1	Physiology	198
5.5.7.2	Mechanism of Action	198
5.5.8	Calcitonin	199
5.5.8.1	Physiology	199
5.5.8.2	Mechanism of Action	199
5.5.9	Calcium and Vitamin D	199
5.5.9.1	Physiology	199
5.5.9.2	Mechanism of Action	199
	Practice-Based Questions	202
	References	205

CHAPTER 6	Reproductive Organ Therapies	215
6.1	Polycystic Ovary Syndrome	215
6.1.1	Biguanides (Metformin)	215
6.1.1.1	Physiology	215
6.1.1.2	Mechanism of Action	217
6.1.2	Combination Oral Contraceptive Pills	219
6.1.2.1	Physiology	219
6.1.2.2	Mechanism of Action	221
6.1.3	Mineralocorticoid Antagonists	222
6.1.3.1	Physiology	222
6.1.3.2	Mechanism of Action	222
6.1.4	Gonadotropins	223
6.1.4.1	Physiology	223
6.1.4.2	Mechanism of Action	225
6.1.5	Clomiphene Citrate	226
6.1.5.1	Physiology	226
6.1.5.2	Mechanism of Action	226
6.1.6	Letrozole	227
6.1.6.1	Physiology	227
6.1.6.2	Mechanism of Action	227
6.1.7	Androgen Receptor Antagonist	227
6.1.7.1	Physiology	227
6.1.7.2	Mechanism of Action	228
6.1.8	5-Alpha Reductase Inhibitor (Finasteride)	228
6.1.8.1	Physiology	228
6.1.8.2	Mechanism of Action	229
6.1.9	Weight loss interventions	229
6.1.9.1	Physiology	229
6.1.9.2	Mechanism of Action	229

6.2	Male Hypogonadism	230
6.2.1	Testosterone Hormone Replacement	230
6.2.1.1	Physiology	230
6.2.1.2	Mechanism of Action	232
6.2.2	Human Chorionic Gonadotropin	234
6.2.2.1	Physiology	234
6.2.2.2	Mechanism of Action	234
6.2.3	Follicle-Stimulating Hormone	235
6.2.3.1	Physiology	235
6.2.3.2	Mechanism of Action	236
6.2.4	Clomiphene Citrate	237
6.2.4.1	Physiology	237
6.2.4.2	Mechanism of Action	237
6.3	Menopause	238
6.3.1	Menopausal Hormone Therapy	238
6.3.1.1	Physiology	238
6.3.1.2	Mechanism of Action	239
6.3.2	SSRI/SNRI	241
6.3.2.1	Physiology	241
6.3.2.2	Mechanism of Action	241
6.4	Turner's Syndrome	242
6.4.1	Hormone Replacement Therapy	242
6.4.1.1	Physiology	242
6.4.1.2	Mechanism of Action	242
6.4.2	Therapies for Metabolic Disorders	243
6.4.2.1	Physiology	243
6.4.2.2	Mechanism of Action	243
6.4.3	Therapies for Linear Growth	243
6.4.3.1	Physiology	243
6.4.3.2	Mechanism of Action	243
	Practice-Based Questions	244
	References	248
CHAPTER 7	Therapies in Disorders of Lipid Metabolism and Obesity	256
7.1	Hyperlipoproteinemia Syndromes	256
7.1.1	Ezetimibe	256
7.1.1.1	Physiology	256
7.1.1.2	Mechanism of Action	259
7.1.2	Statins	261
7.1.2.1	Physiology	261
7.1.2.2	Mechanism of Action	261
7.1.3	PCSK9-Inhibitors	263
7.1.3.1	Physiology	263
7.1.3.2	Mechanism of Action	264
7.1.4	Omega-3 Fatty Acids	265
7.1.4.1	Physiology	265
7.1.4.2	Mechanism of Action	265
7.1.5	Fibrates	266
7.1.5.1	Physiology	266
7.1.5.2	Mechanism of Action	267
7.1.6	Inclisiran	268
7.1.6.1	Physiology	268
7.1.6.2	Mechanism of Action	268
7.1.7	Niacin	270
7.1.7.1	Physiology	270
7.1.7.2	Mechanism of Action	270

7.2	Obesity	271
7.2.1	Phentermine-Topiramate	271
7.2.1.1	Physiology	271
7.2.1.2	Mechanism of Action	272
7.2.2	Liraglutide	273
7.2.2.1	Physiology	273
7.2.2.2	Mechanism of Action	274
7.2.3	Bupropion-Naltrexone	275
7.2.3.1	Physiology	275
7.2.3.2	Mechanism of Action	275
7.2.4	Intestinal Lipase Inhibitor	276
7.2.4.1	Physiology	276
7.2.4.2	Mechanism of Action	276
7.2.5	Bariatric Surgery	277
7.2.5.1	Physiology	277
7.2.5.2	Mechanism of Action	277
7.3	Lipodystrophy Syndromes	280
7.3.1	Insulin Sensitizers	280
7.3.1.1	Physiology	280
7.3.1.2	Mechanism of Action	282
7.3.2	Leptin	282
7.3.2.1	Physiology	282
7.3.2.2	Mechanism of Action	283
	Practice-Based Questions	284
	References	287

CHAPTER 8	Miscellaneous Topics in Disorders of Endocrine Glands	295
8.1	Recent Technological Advances in Diabetes Care	295
8.1.1	Insulin Pumps	295
8.1.2	Continuous Glucose Monitors	295
8.1.2.1	A Brief History of Glucose Monitoring	295
8.1.3	Pumps and CGMs in Practice	297
8.2	Immune Checkpoint Inhibitor-Related Endocrinopathies	299
8.2.1	Hypophysitis	299
8.2.1.1	Checkpoints in Immune Regulation	299
8.2.1.2	Hypophysitis – An Immune-Related Adverse Reaction	301
8.2.2	Thyroid Dysfunction	301
8.2.3	Autoimmune Diabetes	301
8.2.4	Hypoparathyroidism	301
8.3	Pseudoendocrine Conditions	301
8.3.1	Adrenal Fatigue	301
8.3.2	Relative Adrenal Insufficiency	302
8.3.3	Low T3 Syndrome	302
8.3.4	Hashimoto Encephalopathy	303
8.4	Drugs of Abuse with Endocrine Side Effects	303
8.4.1	Cannabis	303
8.4.1.1	Effects of THC on the Hypothalamic–Pituitary–Gonadal (HPG) Axis	304
8.4.1.2	Effects of THC on Energy Homeostasis and Metabolic Regulation	304
8.4.2	Opioids	304
8.4.2.1	Effects of Opioids on the Hypothalamic–Pituitary–Adrenal (HPA) Axis	304
8.4.2.2	Effects of Opioids on the Hypothalamic–Pituitary–Gonadal (HPG) Axis	304

8.4.3	Amphetamines	305
8.4.3.1	Effects on the Hypothalamic–Pituitary–Adrenal Axis	305
8.4.3.2	Effects on the Thyroid	305
8.4.4	Anabolic Androgenic Steroids	305
8.4.5	SERMs	305
	Practice-Based Questions	306
	References	309

CHAPTER 9	Dynamic Tests in Clinical Endocrinology	313
9.1	Pituitary Gland	313
9.1.1	ACTH Stimulation Test (Adrenal Insufficiency)	313
9.1.1.1	Physiology	313
9.1.1.2	Mechanism of Action	313
9.1.1.3	Practice Guide	314
9.1.2	ACTH Stimulation Test (Non-Classic Adrenal Hyperplasia)	315
9.1.2.1	Physiology	315
9.1.2.2	Mechanism of Action	315
9.1.2.3	Practice Guide	315
9.1.3	Dexamethasone Suppression Test	315
9.1.3.1	Physiology	315
9.1.3.2	Mechanism of Action	316
9.1.3.3	Practice Guide	316
9.1.4	Glucagon Stimulation Test	318
9.1.4.1	Physiology	318
9.1.4.2	Mechanism of Action	318
9.1.4.3	Practice Guide	318
9.1.5	Growth Hormone Suppression Test	319
9.1.5.1	Physiology	319
9.1.5.2	Mechanism of Action	319
9.1.5.3	Practice Guide	319
9.1.6	Water Deprivation Test	320
9.1.6.1	Physiology	320
9.1.6.2	Mechanism of Action	320
9.1.6.3	Practice Guide	320
9.1.7	Inferior Petrosal Sinus Sampling	321
9.1.7.1	Physiology	321
9.1.7.2	Mechanism of Action	322
9.1.7.3	Practice Guide	322
9.1.8	TRH Stimulation Test	322
9.1.8.1	Physiology	322
9.1.8.2	Mechanism of Action	323
9.1.8.3	Practice Guide	323
9.1.9	GnRH Stimulation Test	323
9.1.9.1	Physiology	323
9.1.9.2	Mechanism of Action	323
9.1.9.3	Practice Guide	323
9.2	Disorders of the Thyroid Gland	323
9.2.1	Levothyroxine Absorption Test	323
9.2.1.1	Physiology	323
9.2.1.2	Mechanism of Action	324
9.2.1.3	Practice Guide	324
9.2.2	Radioactive Iodine Scans in Thyroid Cancer (Withdrawal)	324
9.2.2.1	Physiology	324
9.2.2.2	Mechanism of Action	325
9.2.2.3	Practice Guide	325

9.2.3	Radioactive Iodine Scans in Thyroid Cancer (Thyrogen)	325
9.2.3.1	Physiology	325
9.2.3.2	Mechanism of Action	326
9.2.3.3	Practice Guide	326
9.3	Disorders of the Adrenal Glands	326
9.3.1	Oral Sodium Loading Test	326
9.3.1.1	Physiology	326
9.3.1.2	Mechanism of Action	326
9.3.1.3	Practice Guide	326
9.3.2	Intravenous Saline Suppression Test	327
9.3.2.1	Physiology	327
9.3.2.2	Mechanism of Action	327
9.3.2.3	Practice Guide	327
9.3.3	Clonidine Suppression Test	327
9.3.3.1	Physiology	327
9.3.3.2	Mechanism of Action	327
9.3.3.3	Practice Guide	328
9.3.4	Insulin Tolerance Test	328
9.3.4.1	Physiology	328
9.3.4.2	Mechanism of Action	328
9.3.4.3	Practice Guide	328
9.3.5	Adrenal Venous Sampling	328
9.3.5.1	Physiology	328
9.3.5.2	Mechanism of Action	329
9.3.5.3	Practice Guide	329
9.4	Disorders of the Pancreas	329
9.4.1	Oral Glucose Tolerance Test	329
9.4.1.1	Physiology	329
9.4.1.2	Mechanism of Action	329
9.4.1.3	Practice Guide	330
9.4.2	The 72-Hour Fast	330
9.4.2.1	Physiology	330
9.4.2.2	Mechanism of Action	331
9.4.2.3	Practice Guide	331
9.4.3	The Secretin Stimulation Test	331
9.4.3.1	Physiology	331
9.4.3.2	Mechanism of Action	331
9.4.3.3	Practice Guide	331
9.5	Disorders of the Reproductive Organs	332
9.5.1	Progestin Challenge Test	332
9.5.1.1	Physiology	332
9.5.1.2	Mechanism of Action	332
9.5.1.3	Practice Guide	332
	Practice-Based Questions	333
	References	335
	Appendix A	343
A.1	Cardiovascular Outcome Trials in Diabetes Care	343
A.2	Common Side Effects of Endocrine Treatments (Board Review)	344
A.2.1	Pituitary Therapies	344
A.2.2	Thyroid Therapies	345
A.2.3	Adrenal Therapies	345
A.2.4	Pancreas-Related Therapies	345
A.2.5	Parathyroid-Related Therapies	345
A.2.6	Obesity and Lipid-Related Therapies	345

A.3	Brand Names of Common Medications in Endocrinology	346
A.3.1	<i>Diabetes Therapies</i>	346
A.3.2	<i>Pituitary-Related Therapies</i>	346
A.3.3	<i>Thyroid Hormone Therapies</i>	346
A.3.4	<i>Reproductive Endocrinology Therapies</i>	347
A.3.5	<i>Obesity and Lipid-Lowering Therapies</i>	347
	Index	348